EPIDEMIOLOGIC AND ECONOMIC IMPACT OF ROUTINE VACCINATION OF INFANTS AGAINST ROTAVIRUS GASTROENTERITIS IN GERMANY: A PRELIMINARY ANALYSIS

Hammerschmidt T1, Forster J2, Huppertz H1, Heininger U1, Roos R3, Standaert BA4

1GlaxoSmithKline, Munich, Germany; 2St. Josefs-Hospital, Freiburg, Germany; 3Prof.-Hess Children’s Hospital, Bremen, Germany; 4University-Children’s Hospital Basel, Basle, Switzerland

OBJECTIVES: Rotavirus gastroenteritis (RVGE) is among the most common reasons for physician consultations during the first year’s of life. RVGE can be prevented by vaccination. The objective was to analyse the clinical and economic impact of universal rotavirus vaccination of infants in Germany. METHODS: A Markov model was developed and calibrated to reflect observed epidemiological data. In the model, a cohort of 670,000 newborns was followed over five years. Routine vaccination with the oral vaccine RotarixTM was compared with no vaccination. Efficacy derived from a European phase-III trial (eTact;102247/NCT140686) demonstrated 87% efficacy against RVGE of any severity, 96% against severe RVGE and 100% against hospitalisation due to RVGE. Total costs to society were 432 € per outpatient, 2,085 € per community-acquired hospitalisation, and 478 € for nosocomial RV cases. Utility values were 0.546 for mild, 0.339 for severe, 0.312 for hospitalized, and 0.501 for hospitalized cases. Cost/effectiveness were discounted by 4.0%/1.5%. Sensitivity analyses were conducted on costs ±15%, utilities ±15%, efficacy (95%CI), discounting and vaccine price (within study). RESULTS: In the cohort, 182,820 community-acquired cases (140,785 presenting to physicians and of those 33,081 were hospitalized) and 19,984 nosocomial cases occurred resulting in costs of 128.2 mio. €. The overall number of cases could be reduced by 82.0%. Approximately 4 children had to be vaccinated to prevent one community-acquired, hospitalized case. Cost-effectiveness was 3,770 € per QALY. Cost/QALY was below 15,000 € for all sensitivity analyses, the cost/QALY being most sensitive to variations in cost assumptions. At higher costs, lower vaccine price and without discounting, vaccination was cost-saving. CONCLUSION: Rotavirus causes a considerable burden of disease and associated costs. Universal vaccination of infants is a cost-effective approach to reducing this socio-economic burden.

BURDEN OF PAEDIATRIC ROTAVIRUS GASTROENTERITIS AND POTENTIAL BENEFITS OF A UNIVERSAL VACCINATION PROGRAMME IN GERMANY

Buesch K1, Ezzat N2, Trichard M2, Llargeron N3

1Sanofi Pasteur MSD, Leimen, Germany; 2Alpha Care GmbH, Celle, Germany; 3Sanofi pasteur MSD, Lyon, France

OBJECTIVES: Rotavirus is the most common cause of gastroenteritis in young children worldwide, resulting in a high burden of disease. The objective of this study was to evaluate the effects of vaccinating infants with a pentavalent rotavirus vaccine, RotaTeq®, in Germany. METHODS: Using a decision analytic model a birth cohort of 705,622 newborns was followed from birth up to 5 years of age. Total societal cost associated with rotavirus gastroenteritis in this cohort was calculated. Potential costs and benefits of a universal rotavirus vaccination programme were assessed. Input parameters were derived from a German prospective epidemiological study (“REVEAL study”), national statistics and published literature. Efficacy of RotaTeq® (prevention of 86% office visits, of 96% hospitalisations) was based on a large clinical trial (“REST Efficacy Study”, Phase III). Main outcome measures were cases avoided, total societal direct and indirect disease costs and vaccination expenditures of SIckness Funds (administration fees & vaccine costs). Cost per avoided case was used as a measure of cost-effectiveness. In addition, the number needed to vaccinate (NNV) was calculated. RESULTS: A rotavirus vaccination programme with a coverage rate of 90% would prevent in total about 325,565 cases of rotavirus infections in Germany (~75%) and the huge burden of human suffering behind these cases. Total societal costs associated with paediatric rotavirus gastro-enteritis are estimated at €119.2 million. The vaccination programme with cost of €117.2 million could reduce the societal disease costs by €91.8 million (~77%). This leads to costs per hospitalised case avoided of €1405.70 and a NNV of 35 infants. To avoid 1 general practitioner/paediatrician case the NNV is 6 with costs per case prevented of €191,90. CONCLUSION: Implementing a rotavirus vaccination programme in Germany with RotaTeq® will significantly and efficiently decrease the morbidity and associated burden due to rotavirus infections in young children. –2007–.